A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer

被引:3
|
作者
Magno, Elizabeth [1 ]
Bussard, Karen M. [1 ]
机构
[1] Thomas Jefferson Univ, Dept Pharmacol Physiol & Canc Biol, Philadelphia, PA 19107 USA
关键词
breast cancer; bone; bone metastasis; tumor microenvironment; chemotherapy; endocrine therapy; radiation therapy; bone modifying agents; bisphosphonates; NEOADJUVANT ENDOCRINE THERAPY; SUPERVISED RISK PREDICTOR; PHASE-II TRIAL; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ADJUVANT DENOSUMAB; RADIATION-THERAPY; AMERICAN SOCIETY; ZOLEDRONIC ACID; OPEN-LABEL;
D O I
10.3390/ijms25063407
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite treatment advances, breast cancer remains a leading cause of death of women in the United States, mostly due to metastatic disease. Bone is a preferential site for breast cancer metastasis, and most metastatic breast cancer patients experience bone involvement at the time of death. The majority of patients with bone metastatic breast cancer are first diagnosed with and treated for early-stage disease, and from development of early-stage breast cancer to the recurrence of cancer in the bones, up to 30 years may elapse. Throughout this timeframe, a typical patient undergoes many treatments that have effects on the bone microenvironment. Therefore, this review explores the clinical course of a representative patient with hormone receptor-positive bone metastatic breast cancer, examining key treatment options at each stage and their effects on preventing and treating bone metastases.
引用
收藏
页数:27
相关论文
共 50 条
  • [1] Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
    Falato, Claudette
    Schettini, Francesco
    Pascual, Tomas
    Braso-Maristany, Fara
    Prat, Aleix
    CANCER TREATMENT REVIEWS, 2023, 112
  • [2] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Jin, Xi
    Zhou, Yi-Fan
    Ma, Ding
    Zhao, Shen
    Lin, Cai-Jin
    Xiao, Yi
    Fu, Tong
    Liu, Cheng-Lin
    Chen, Yi-Yu
    Xiao, Wen-Xuan
    Liu, Ya-Qing
    Chen, Qing-Wang
    Yu, Ying
    Shi, Le-Ming
    Shi, Jin-Xiu
    Huang, Wei
    Robertson, John F. R.
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE GENETICS, 2023, 55 (10) : 1696 - +
  • [3] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [4] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [5] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [6] Evolving treatment patterns in hormone receptor-positive, HER2-negative metastatic breast cancer
    Lankford, M. L.
    Britton, S. L.
    Buettner, A. D.
    Scharf, M.
    Tiscione, B.
    Willey, J. P.
    Mahtani, R. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [7] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [8] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
  • [9] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [10] Alternative Palbociclib Dosing Schedules for Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Kamei, Keitaro
    Noguchi, Yoshinori
    Usami, Eiseki
    Yoshimura, Tomoaki
    ONCOLOGY, 2024,